Faron Pharmaceuticals Oy Balance Sheet Health
Financial Health criteria checks 6/6
Faron Pharmaceuticals Oy has a total shareholder equity of €1.4M and total debt of €12.4M, which brings its debt-to-equity ratio to 897.6%. Its total assets and total liabilities are €35.5M and €34.1M respectively.
Key information
897.6%
Debt to equity ratio
€12.38m
Debt
| Interest coverage ratio | n/a |
| Cash | €29.98m |
| Equity | €1.38m |
| Total liabilities | €34.08m |
| Total assets | €35.46m |
Recent financial health updates
Recent updates
Financial Position Analysis
Short Term Liabilities: 4FR's short term assets (€34.0M) exceed its short term liabilities (€23.5M).
Long Term Liabilities: 4FR's short term assets (€34.0M) exceed its long term liabilities (€10.6M).
Debt to Equity History and Analysis
Debt Level: 4FR has more cash than its total debt.
Reducing Debt: 4FR had negative shareholder equity 5 years ago, but is now positive and has therefore improved.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: 4FR has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: 4FR has sufficient cash runway for 1.5 years if free cash flow continues to reduce at historical rates of 6% each year.